Ott O (2025)
Publication Type: Journal article
Publication year: 2025
DOI: 10.1007/s11654-025-00685-6
Muscle-invasive bladder cancer still represents a therapeutic challenge. Both radical cystectomy (RC) and bladder-sparing trimodality treatment (TMT) are considered equally effective in terms of major oncological endpoints in carefully selected patients. Trimodality treatment is an interdisciplinary approach consisting of initial transurethral resection (TUR) of the bladder tumor followed by simultaneous chemoradiation (RCT) and obligatory reevaluation TUR 6–12 weeks after the end of RCT. Adherence to published quality criteria, e.g., complete initial TUR or combining radiotherapy with simultaneous radiosensitizing chemotherapy, is essential for successful TMT. Comparative randomized data on RC and TMT are not available, as this kind of trial with randomization to surgery vs. a nonsurgical approach is generally not well accepted by patients. The best evidence on major oncological endpoints such as overall and cancer-specific survival is derived from meta-analyses of matched cohorts and showed no advantage for RC compared to TMT. A number of studies combining TMT with modern immune checkpoint inhibitors (ICI) are currently underway. Although ICI have already shown efficacy in locally advanced and metastasized bladder cancer, no practice-changing results have been published so far in combination with TMT. However, as the trials mature, it is expected that ICI will impact and modify the current bladder-conserving standard treatments in the near future.
APA:
Ott, O. (2025). Organ-preserving treatment for muscle-invasive bladder cancer Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms. Best Practice Onkologie. https://doi.org/10.1007/s11654-025-00685-6
MLA:
Ott, Oliver. "Organ-preserving treatment for muscle-invasive bladder cancer Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms." Best Practice Onkologie (2025).
BibTeX: Download